Bipolar disorder (BD) is a severe psychiatric disorder characterized by phasic changes of mood and can be associated with progressive structural brain change and cognitive decline. The numbers and sizes of glia and neurons are reduced in several brain areas, suggesting the involvement of apoptosis in the pathophysiology of BD. Because the changes in mitochondrial dynamics are closely related with the early process of apoptosis and the specific processes of apoptosis and mitochondrial dynamics in BD have not been fully elucidated, we measured the apoptotic pathway and the expression of mitochondrial fission/fusion proteins from BD patients and healthy controls. We recruited 16 patients with BD type I and sixteen well-matched healthy controls and investigated protein levels of several pro-apoptotic and anti-apoptotic factors, as well as the expression of mitochondrial fission/fusion proteins in peripheral blood mononuclear cells (PBMCs). Our results showed that the levels of the anti-apoptotic proteins Bcl-xL, survivin and Bcl-xL/Bak dimer were significantly decreased, while active caspase-3 protein levels were significantly increased in PBMCs from BD patients. Moreover, we observed the downregulation of the mitochondrial fusion-related proteins Mfn2 and Opal and the upregulation of the fission protein Fis1 in PBMCs from BD patients, both in terms of gene expression and protein levels. We also showed a significantly decrease in the citrate synthase activity. Finally, we found a positive correlation between Mfn2 and Opal with mitochondrial content markers, as well as a negative correlation between mitochondrial fission/fusion proteins and apoptotic markers. Overall, data reported here are consistent with the working hypothesis that apoptosis may contribute to cellular dysfunction, brain volume loss and progressive cognitive in BD. Moreover, we show an important relationship between mitochondrial dynamics and the cell death pathway activation in BD patients, supporting the link between mitochondrial dysfunction and the pathophysiology of BD.

INTRODUCTION

Bipolar disorder (BD) is a chronic, debilitating illness with a global prevalence of up to 4.8%, which is associated with medical and psychiatric comorbidity and increased standardized mortality ratios.1,2 Acute episodes are associated with cognitive and functional impairments,3 which tend to worsen with the progression of the illness.4-7 Despite superior cognitive capacity often present in at risk-individuals,8 individuals with a long-term course of illness present significant impairment in neuropsychological performance when compared to early-stage patients and controls.4,9

Although several different mechanisms have been proposed for the pathogenesis of BD, its pathophysiology remains unknown.10 Numerous hypotheses have been postulated to underpin the neurobiology of BD, including the interaction of molecular, cellular and behavioral mechanisms with susceptibility genes, environmental stressors and biochemical mechanisms.4 Regional reductions in central nervous system volume, which are likely due to the atrophy of neurons and glial cells, may be linked to an increase or imbalance in apoptosis,11-13 and it is known that mitochondria play a critical role in the regulation of apoptosis.14 Kim et al.12 reported a significant decrease in the levels of Bcl-2 and brain-derived neurotrophic factor, whereas Bax, Bad and caspase-9/-3 levels were significantly increased, both in terms of protein and mRNA levels in postmortem brains of BD patients. A recent clinical study also showed an increase in the Bax/Bcl-2 ratio and increased cytochrome c release and caspase-3 activity in manic and depressed patients compared to healthy subjects.15 Similarly, lymphocytes from patients with BD present decreased expression of the HSP70, an anti-apoptotic factor, as well as a decrease in Bax levels in the cytosolic fraction, suggesting Bax activation and translocation to the mitochondria to induce apoptosis.16 Moreover, a study published by Fries et al.17 showed an increased percentage of early apoptotic cells in euthymic...
patients with BD when compared to controls, but no differences in overall cell viability, necrosis or late apoptosis, suggesting potential plasticity and an intervention opportunity.

Mitochondria are organelles responsible for multiple cellular functions, including ATP production, metabolism of reactive oxygen species and calcium homeostasis. Moreover, they represent a convergence point for death signals activated by both intracellular and extracellular stimuli, leading to the release of apoptosis-inducing factor, and SMAC/Diablo. In addition, recent studies indicate that mitochondrial fission/fusion machinery actively participates in the process of apoptosis, since dysregulation of mitochondrial dynamics leads to mitochondrial fragmentation. However, the specific processes of apoptosis and mitochondrial dynamics in BD have not been fully elucidated. To test the above hypothesis, we measured the protein levels of several pro- (Bax, Bad, Bak, Smac and active caspase-3) and anti-apoptotic factors (Bcl-xl, Bcl-xl/Bak dimer, survivin and Mcl-1), the mRNA and protein expression levels of mitochondrial fission/fusion proteins (Mfn2, Opa1 and Fis1), and the mitochondrial content in peripheral blood mononuclear cells (PBMCs) from BD patients and healthy controls.

MATERIALS AND METHODS

Subjects
This study was carried out in accordance with the principles of the Declaration of Helsinki with approval from the Institutional Review Board of the University of Texas Health Science Center at Houston, and written informed consent was obtained from all research participants. Sixteen participants with BD type I were recruited from the UTHealth Mood Disorders outpatient clinic, and 16 healthy controls were recruited from the local community and did not have a personal psychiatric disorder or family history of major psychiatric disorder or neurologic disorders in first-degree relatives. Specific inclusion criteria for the BD patients were as follows: (a) patients with diagnosis of BD I, based on DSM-IV criteria; (b) 18–65 years old; (c) BD patients at any current mood state at the time of the study; (d) BD patients preferably off pharmacological treatment at the time of assessment of the intrinsic apoptotic pathway

The intrinsic apoptotic pathway was assayed using multiplex fluorescent immunoassay kits (Bio-Plex Pro RBM apoptosis assays). The xMAP platform used here was based on the Rules-Based Medicine (RBMM) fluorescent beads and antibody pairs. These are sensitive, specific and widely used reagents, sourced by numerous manufacturer’s and the data collected using xMAP multiplex beads are widely reported in the literature in studies in which multiple proteins are assayed simultaneously. Total cellular extracts from the PBMC cells were prepared by lysing the cells in lysate dilution buffer following an appropriate post-processing delay.

Quantification of the intrinsic apoptotic pathway

The intrinsic apoptotic pathway was assayed using multiplex fluorescent immunoassay kits (Bio-Plex Pro RBM apoptosis assays). The xMAP platform used here was based on the Rules-Based Medicine (RBMM) fluorescent beads and antibody pairs. These are sensitive, specific and widely used reagents, sourced by numerous manufacturer’s and the data collected using xMAP multiplex beads are widely reported in the literature in studies in which multiple proteins are assayed simultaneously. Total cellular extracts from the PBMC cells were prepared by lysing the cells in lysate dilution buffer according to the manufacturer’s instructions, followed by centrifugation at 4°C for 10 min at 10,000 g.

The assays were conducted in 96-well polystyrene, round-bottom microplates. Initially, blocker (10 μl) was added to all wells of the plate. Next, 30 μl of the standard, control or total extracts were added to each well, as indicated. A 10 μl aliquot of the working bead mixture was transferred into the wells. The plate was incubated on a plate shaker (850 r.p.m.) in the dark at RT for 60 min. The plate was then placed in the magnetized separator and incubated for 10 min. The supernatant was carefully removed from each well by manual inversion. Beads were washed 3 times by adding 100 μl of assay buffer into each well to ensure the absence of any undesirable or non-specifically bound antibodies. After this protocol, 40 μl of a detection antibody were added to each well. Incubation was again conducted in darkness and at RT on a plate shaker (850 r.p.m.) for 60 min. Finally, 20 μl of streptavidin-PE was added to each well. The plate was incubated on a plate shaker (850 r.p.m.) in the dark at RT for 30 min. The supernatant was carefully removed after magnetic separation of the beads by manual inversion, and washing was performed as previously described. Assay buffer (100 μl) was added into each well, and the plate was placed onto a plate shaker for approximately 30 s in order to achieve gentle agitation of the beads. Samples were run in duplicate using a Bioplex system (Bio-Plex 200 Systems, BioRad, Hercules, CA, USA) and data analysis was conducted in Bio-Plex Manager 4.0 using a 5-parameter logistic regression model.

Gene expression

PBMCs from each subject were used for total RNA isolation using the RNeasy Plus Mini Kit (Qiagen, Germantown, MD, USA), according to the manufacturer’s instructions. After quantification on NanoDrop (Uniscience, Hialeah, FL, USA), the RNA samples were converted to complementary DNA (cDNA) with the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA, USA). The cDNA synthesis was performed in a final volume of 10 μl with 2 μl 10x RT buffer, 0.8 μl 25× dNMT Mix, 2 μl 10× RT random primers and 1 μl MultiScribe reverse-transcriptase (50 units per ml), and the reactions were incubated for 10 min at 25°C, 2 h at 37°C, and 5 s at 85°C. Real-time quantitative reverse-transcriptase PCR (qRT–PCR) reactions were performed for the assessment of Mfn1, Mfn2, Opa1, Drp1 and Fis1 gene expression using specific TaqMan FAM/MGB assays (Applied Biosystems, ID assay Hs00966851_m1 for Mfn1, ID assay Hs00208382_m1 for Mfn2, ID assay Hs01047018_m1 for Opa1, ID assay Hs01552605_m1 for Drp1, and Hs00211420_m1 for Fis1). GAPDH (Applied Biosystems, VIC/MGB assay ID Hs99999905_m1) was used as the endogenous control. Reactions were performed in triplicate in a final volume of 12 μl containing 6 μl 2× TaqMan Gene Expression Master Mix, 0.6 μl 20× TaqMan Gene Expression Assay, 0.6 μl 20× TaqMan Endogenous Control, 3.8 μl of water, and 1 μl of cDNA solution, and were run in a QuantStudio 7 Flex Real-Time PCR System (ThermoFisher). Gene expression levels were analyzed by the ddCt method.

Enzyme-linked immunosorbornt assay

Proteins were extracted from PBMCs using 1× Cell Lysis Buffer (Bio-Plex Cell Lysis Kit, Bio-Rad, Hercules, CA, USA) containing 500 mM PMSF (Sigma-Aldrich, St. Louis, MO, USA). Insoluble debris were removed by centrifugation at 4500 g for 20 min at 4°C. Total protein concentration was determined using a BCA assay (Thermo Scientific Pierce). Afterwards, Mfn1, Mfn2, Opa1, Fis1 and Drp1 levels were determined using sandwich-ELISA assays (MyBioSource, San Diego, CA, USA) according to the manufacturer’s instructions. The standard curve demonstrated a direct relationship between optical density (OD) and protein concentration.

Citrate synthase activity

Citrate synthase activity was assayed according to the method described by Sere, with a reaction mixture containing 100 mM Tris, pH 8.0, 0.1 mM acetyl CoA, 0.1 mM 5,5′-di-thiobis-(2-nitrobenzoic acid), 0.1% triton X-100, and 2–4 μg supernatant protein. The enzymatic reaction was initiated with 0.2 μl oxaloacetate and monitored at 412 nm for 3 min at 25°C.

mtDNA copy number

Real-time quantitative (PCRs) were performed to measure the amount of mitochondrial DNA relative to a single-copy gene (beta-hemoglobin) with a modified protocol from Tyrka and collaborators. Reactions included 25 ng genomic DNA, 300 nM i 1× of each primer, and 1× Sybr Select Master Mix (Life Technologies, Carlsbad, CA, USA) in a final volume of 10 μl.
Primer sequences and PCR cycling conditions for both mtDNA and beta-hemoglobin have been previously reported. Reactions were carried out in 96-well plates and data were acquired in a QuantStudio 7 Flex Real-Time PCR System (Life Technologies). mtDNA copy number for each sample was determined by relative quantification based on a 5-point standard curve performed with a serial dilution (1:2) of a calibrator sample ranging from 1 to 0.0625 ng DNA. All samples were analyzed in triplicate. The relative amount of mtDNA was finally divided by the relative amount of the beta-hemoglobin gene to obtain an index of mitochondrial DNA copy number.

Statistical analysis
Statistical analyses were performed using Statistical Package for the Social Sciences, v.23.0 (SPSS, Armonk, NY, USA). Descriptive statistics were used to report demographic and clinical characteristics of the sample. Normality of data distribution was assessed using the Shapiro-Wilk test and histogram visualization. Since the variables being analyzed did not follow a normal distribution, the nonparametric Mann–Whitney U-test was used to test significant differences between the groups. Categorical variables were compared using chi-square or Fisher’s exact tests. Correlation analyses were performed using Spearman’s rank correlation test. Data are presented as median and interquartile range (IQR). Significance was set at \( P < 0.05 \). Analyses of covariance were used to adjust for possible confounders. We considered all variables associated with diagnostic group and markers with \( P < 0.20 \) to be possible confounding factors.

RESULTS
Characteristics of BD participants and healthy controls are shown in Table 1. The intrinsic apoptotic pathway and mitochondrial dynamics were evaluated in 16 participants with BD and 16 healthy controls. Notably, no significant differences in socio-demographic factors (ethnicity, socioeconomic status, age, gender, body mass index, education and smoking status) emerged between groups. The mean YMRS score of the BD group was 7.75 ± 6.97, and their mean MADRS score was 13.81 ± 10.94. Moreover, a significant difference in functional status, assessed by GAF (\( P < 0.0001 \)) and FAST (\( P < 0.0001 \)), was found between healthy controls and patients with BD. All patients were on treatment with various psychiatric medications at conventional

### Table 1. Demographic characteristics of all subjects

|                         | Healthy subjects | Bipolar subjects | P-value |
|-------------------------|------------------|------------------|---------|
| n                       | 16               | 16               |         |
| Mean age, years         | 33.75 ± 8.85     | 35.18 ± 8.86     | 0.416   |
| Female gender, n (%)    | 8 (50%)          | 8 (50%)          | 0.638   |
| Ethnicity (non-Hispanic)| 14 (87.5%)       | 12 (75%)         | 0.327   |
| Education (years)       | 14.69 ± 1.66     | 13.56 ± 1.86     | 0.677   |
| Body mass index         | 27.43 (5.82)     | 28.22 (6.38)     | 0.717   |
| Smoking                 | 18.80%           | 37.50%           | 0.217   |
| MADRS                   | 0.19 (0.403)     | 13.81 (10.94)    | < 0.0001|
| YMRS                    | 0.13 (0.342)     | 7.75 (6.97)      | < 0.0001|
| GAF                     | 90.13 (3.934)    | 56.00 (11.95)    | < 0.0001|
| FAST                    | 5.36 (6.985)     | 34.00 (16.215)   | < 0.0001|
| Number of manic episodes| NA               | 27.38 (49.10)    |         |
| Number of hypomanic episodes| NA         | 44.75 (41.02)   |         |
| Number of depressive episodes| NA          | 29.80 (55.56)   |         |
| Number of mixed episodes| NA               | 38.00 (50.56)    |         |
| Number of hospitalizations| NA             | 2.63 (3.70)     |         |
| Illness duration        | NA               | 17.43 (7.78)     |         |
| Age at first mania episode| NA            | 19.11 (6.60)    |         |
| Age at first depressive episode| NA        | 15.31 (6.43)    |         |
| Psychiatric medications (%)|                |                  |         |
| Lithium                 | NA               | 25.00%           |         |
| Antidepressants         | NA               | 31.30%           |         |
| Antipsychotics          | NA               | 43.80%           |         |
| Anticonvulsant          | NA               | 37.50%           |         |
| Benzodiazepines         | NA               | 18.80%           |         |
| Stimulants              | NA               | 6.30%            |         |

Abbreviations: FAST, Functioning Assessment Short Test; GAF, Global Assessment of Functioning; MADRS, Montgomery–Åsberg Depression Rating Scale; NA, not applicable; YMRS, Young Mania Rating Scale.

Figure 1. Alteration of anti- and pro-apoptotic proteins in peripheral blood mononuclear cells (PBMCs) from healthy controls and patients with Bipolar Disorder type I (BD-I). (a) Protein levels of Bcl-xL, (b) Protein levels of Bcl-xL/Bak dimer, (c) Protein levels of survivin and (d) Protein levels of active caspase-3. Data were presented as median and interquartile range (IQR). Differences between 2 groups were compared using the Mann–Whitney U-test. Different from the control group; \( *P < 0.05 \).
doses at the time of the study, including antipsychotics, anti-convulsants, mood stabilizers and antidepressants. Some patients received additional benzodiazepines and stimulants.

The role of mitochondrial pathway-mediated apoptosis markers in BD was investigated by analyzing the protein levels of bcl-2 family proteins, survivin, smac, and lamin B using multiplex fluorescent immunoassay kits. The levels of the anti-apoptotic proteins Bcl-xL ($P = 0.002$), Bcl-xL/Bak dimer ($P = 0.001$) and survivin ($P = 0.017$) were significantly lower in PBMCs from the BD group compared to lymphocytes from the healthy control group. However, the levels of active caspase-3 ($P = 0.008$) were significantly higher in lymphocytes from the BD group when compared with healthy controls (Figure 1). In contrast, no differences in the protein levels of the pro-apoptotic factors Bad, Bax, Bad and Smac, or in the anti-apoptotic proteins Mcl-1 and Mcl-1/Bak dimer were found in lymphocytes from the BD group when compared with healthy controls (Supplementary Figure 1S).

To evaluate the mitochondrial dynamics of fusion and fission, we analyzed the mRNA expression and protein levels of Mfn1, Mfn2, Opa1, Drp1 and Fis1. We found that the gene expression of the mitochondrial fusion-related proteins $Mfn2$ ($P = 0.015$) and $Opa1$ ($P = 0.003$) was downregulated in the BD group compared to healthy controls (Figures 2c and e, respectively). On the contrary, the gene expression levels of mitochondrial fission-related protein $Fis1$ ($P = 0.003$) were significantly higher in the BD group compared to healthy controls (Figure 3a). Moreover, there were no significant differences in the gene expression levels of $Mfn1$ and $Drp1$ in PBMCs between healthy controls or BD subjects (Figures 2a and 3c, respectively). The overexpression or reduced expression of mitochondrial fusion/fission proteins was confirmed by ELISA analysis. As expected, the results revealed that the protein levels of Mfn2 ($P = 0.002$) and Opa1 ($P = 0.021$) were significantly decreased in BD patients compared with the controls (Figures 2d and f, respectively), whereas the protein levels of Fis1 ($P = 0.036$) were significantly increased in lymphocytes from the BD group when compared with healthy controls (Figure 3b).

In addition, to establish whether the changes observed in the fusion and fission process occurred in conjunction with alterations in mitochondrial mass, we evaluated mitochondrial content by quantifying mtDNA copy number. We observed no significant

Figure 2. Alteration of mitochondrial fusion proteins in peripheral blood mononuclear cells (PBMCs) from healthy controls and patients with Bipolar Disorder type I (BD-I). (a) Relative mRNA expression of Mfn1, (b) Protein levels of Mfn1 (c) Relative mRNA expression of Mfn2, (d) Protein levels of Mfn2, (e) Relative mRNA expression of Opa1, (f) Protein levels of Opa1. Data were presented as median and interquartile range (IQR). Differences between 2 groups were compared using the Mann–Whitney U-test. Different from the control group; $*P < 0.05$. 

Translational Psychiatry (2017), 1 – 10
Figure 3. Alteration of mitochondrial fission proteins in peripheral blood mononuclear cells (PBMCs) from healthy controls and patients with Bipolar Disorder type I (BD-I). (a) Relative mRNA expression of Fis1, (b) Protein levels of Fis1, (c) Relative mRNA expression of Drp1, (d) Protein levels of Drp1. Data were presented as median and interquartile range (IQR). Differences between 2 groups were compared using the Mann–Whitney U-test. Different from the control group; *P < 0.05.

Figure 4. Mitochondrial mass in in peripheral blood mononuclear cells (PBMCs) from healthy controls and patients with Bipolar Disorder type I (BD-I). (a) Distribution of relative mtDNA copy number, (b) Citrate synthase activity, (c) Correlation coefficient (Pearson’s correlation coefficient) between citrate synthase activity and protein levels of Mfn2, (d) Correlation coefficient (Spearman’s rank correlation test) between citrate synthase activity and protein levels of Opa1. Data were presented as median and interquartile range (IQR). Differences between 2 groups were compared using the Mann–Whitney U-test. Different from the control group; *P < 0.05.
difference in relative mtDNA copy number in the BD group (Figures 4a, \( P = 0.315 \)). To verify whether the mtDNA content in BD was associated with mitochondrial mass, we performed citrate synthase activity assay, an enzymatic marker of mitochondrial mass. We observed a significant decrease in citrate synthase activity in lymphocytes from the BD group when compared with healthy controls (Figures 4b, \( P = 0.017 \)). Moreover, we also observed positive correlations between mtDNA content and citrate synthase activity (rho = 0.457, \( P = 0.017 \)), suggesting a reduced mitochondrial mass in BD patients. Next, we analyzed the relationship between fusion/fission proteins with citrate activity. As seen in Figure 4c, Mfn2 levels were positively correlated with citrate synthase activity (rho = 0.457, \( P = 0.011 \)). The present results also show a statistically significant correlation between Opa1 protein levels and citrate synthase activity (rho = 0.378, \( P = 0.043 \); Figure 4d). No correlations were found between Fis1 protein levels, citrate synthase activity and mtDNA (data not shown).

Since Bcl-2 family members play an active role in the regulation of mitochondrial dynamics, we analyzed the relationship between apoptosis and mitochondrial fission/fusion proteins. The present results show that active caspase-3 was negatively correlated with Mfn2 levels (rho = −0.551, \( P = 0.002 \)) and Opa1 levels (rho = −0.369, \( P = 0.049 \)). Also, a significant negative correlation was found between Bcl-xL and Fis1 levels (rho = −0.604, \( P = 0.001 \)), while a positive correlation was found between Bcl-xL/Bak dimer and Mfn2 levels (rho = 0.389, \( P = 0.041 \); Figure 5). No correlations were found between Mfn2 protein levels and survivin protein levels (rho = 0.065, \( P = 0.748 \)). However, we found a significant positive correlation between Mfn2 mRNA levels and survivin protein levels (rho = 0.432, \( P = 0.024 \)), as well as a positive correlation between Mfn2 mRNA levels and Mfn2 protein levels (rho = 0.420, \( P = 0.021 \)).

Finally, in an attempt to explore the potential clinical correlates of our findings, we tested possible correlations between psychiatric and demographic characteristics and biochemical data. Our results showed no significant differences in the protein levels of apoptotic factors and mitochondrial fission/fusion proteins in patients under treatment with lithium and antipsychotics (data not shown). Moreover, no associations were found between cellular parameters and age, gender, ethnicity, education, body mass index, smoking, number of depressive episodes or number of hospitalizations (\( P > 0.05 \) for all analyses). However, we found a negative correlation between Mfn2 levels and YMRS (rho = −0.554, \( P = 0.001 \), Figure 6a) and MADRS (rho = −0.426, \( P = 0.019 \), Figure 6b) scores, as well as with the number of manic episodes (rho = −0.551, \( P = 0.035 \), Figure 6c). Moreover, we also performed an additional analysis to test the hypothesis that the alterations in anti-apoptotic factors and mitochondrial fission/fusion proteins correlate with the functional status. The results of Spearman’s rank correlation showed a positive correlation between the GAF scores and Mfn2 (rho = 0.598, \( P < 0.001 \), Figure 6d), as well as with the anti-apoptotic factors Bcl-xL (rho = 0.570, \( P = 0.002 \), Figure 6e) and Bcl-xL/Bak dimer (rho = 0.579, \( P = 0.001 \), Figure 6f). Similarly, FAST scores were negatively correlated with Mfn2 (rho = −0.401, \( P = 0.025 \), Figure 6g), Bcl-xL (rho = −0.407, \( P = 0.035 \), Figure 6h) and Bcl-xL/Bak dimer (rho = −0.553, \( P = 0.002 \), Figure 6i).

**DISCUSSION**

Brain imaging studies over the last two decades have confirmed the presence of volumetric abnormalities in patients with BD compared with healthy control subjects, including reductions in gray matter density in the hippocampus, amygdala, frontal cortex, superior temporal gyrus, cerebellum, and ventricular systems.\(^{32-37}\) Previous studies have also reported that the number and size of glia and neurons are reduced in some of these brain areas,\(^{38,39}\) suggesting the involvement of apoptosis in the pathophysiology of BD. However, the specific processes of apoptosis in BD have not been fully elucidated. In this study, we have investigated the levels
of several survival-related and pro-apoptotic proteins in PBMCs of BD participants, and we observed significant alterations compared to healthy controls, including marked decreases in the levels of Bcl-xL, survivin and Bcl-xL/Bak dimers and an increase in the caspase-3 protein levels. Our results are thus in agreement with previous studies showing changes in apoptosis in PBMCs of patients with BD and in postmortem prefrontal cortex from BD patients. Mitochondria play a key role in the regulation of apoptosis. Specifically, the release of various pro-apoptotic proteins that are normally present in the intermembrane space of these organelles, such as the cytochrome c, is observed during the early stages of apoptotic cell death. Anti-apoptotic members of the Bcl-2 family, such as Bcl-2 or Bcl-xL, inhibit Bak or Bak activation, as members of the Bcl-xL protein family contain BH1 and BH2 domains which are required for heterodimerization with Bak and the inhibition of cell apoptosis. Consistent with this, we observed a decrease in Bcl-xL and Bcl-xL/Bak heterodimers, suggesting that Bcl-xL cannot protect against apoptosis by inhibiting Bak oligomerization. This can lead to the formation of mitochondrial pores and allows the release of intermembrane space proteins that can either act as cofactors for the assembly of the Apaf-1/caspase-9 apoptosome or promote other downstream events in apoptosis, ultimately leading to caspase-3 activation and subsequent cell death. Moreover, to our knowledge, this is the first study to show significantly lower levels of survivin in PBMCs of BD patients compared to healthy controls. Survivin, a member of the family of inhibitors of apoptosis proteins (IAPs), is a bifunctional protein that regulates cell division and suppresses apoptosis. It represents a chromosomal passenger protein that binds to caspases, both the effectors caspase-3 and caspase-7 and the initiator caspase-9, thus protecting cells from apoptosis. Iscru et al. (2013) reported that survivin was also involved in LTP in the hippocampus, suggesting that survivin is involved in hippocampal synaptic plasticity either by compromising hippocampal neurogenesis or by direct interactions with signaling cascades such as NF-kappa B that are involved in hippocampal synaptic plasticity and learning. Thus, a marked decrease of survivin in PBMCs of BD patients would change the balance between the levels of active caspases and IAPs, allowing the active caspases to execute apoptosis. Finally, if taken as a proxy of the brain, the decrease detected in our sample could lead to neuronal loss and impaired synaptic plasticity in BD patients. Corroborating this hypothesis, our results showed higher levels of active caspase-3.

Of note, the interplay between the Bcl-2 family and mitochondria is not limited to the intrinsic pathway. Bcl-2 family members...
play an active role in the regulation of mitochondrial dynamics, mitochondrial respiration, metabolism, and apoptotic resistance.\textsuperscript{49–52} In this study, real-time PCR and ELISA were used to measure the expression and protein levels of mitochondrial fusion/fission proteins in PBMCs from BD patients. Compared to healthy controls, BD patients showed downregulation of \textit{Mfn2} and \textit{Opa1} and upregulation of \textit{Fis1} both in terms of gene expression and protein levels. Having analyzed mtDNA, we also observed a trend for a decrease in copy number in the BD group. Our results are in accordance with a previous study in leukocyte mtDNA, which showed a slight decrease in baseline mtDNA content in type I BD compared to controls. Of note, our results show that patients present a decrease in the activity of citrate synthase, a marker of mitochondrial content, which were positively correlated with mtDNA. Moreover, decreased \textit{Mfn2} protein levels were correlated with the activity of citrate synthase and mtDNA, suggesting that \textit{Mfn2} is essential for the regulation of mitochondrial morphology by tipping the balance towards mitochondrial fragmentation. Our results are supported by a study published by Cataldo \textit{et al.}\textsuperscript{53} demonstrating that prefrontal cortex neurons of postmortem brain from patients with BD and peripheral cells from BD patients display morphological abnormalities (more mitochondria of smaller size) and an abnormal pattern of clumping and marginalization in the intracellular distribution of mitochondria. Taken together, these results suggest that these mitochondrial structural abnormalities may represent an attempt to overcome a reduced mitochondrial network connectivity, as determined by the balance between fusion and fission processes.

Several studies have demonstrated that alterations in proteins involved in mitochondrial fusion and fission lead to altered mitochondrial shape, loss of mtDNA, decrease in mitochondrial respiration, increased oxidative stress and apoptotic cell death.\textsuperscript{54–57} \textit{Mfn2} expression controls the expression of oxidative phosphorylation, and the inhibition of \textit{Mfn2} expression is associated with a reduced mitochondrial membrane potential, impaired glucose oxidation and a downregulation of oxidative phosphorylation subunits, all of which markedly alters the extent of the mitochondrial network.\textsuperscript{58,59} \textit{Mfn2} deficiency also increases the mitochondrial \textit{Bax}/\textit{Bcl-2} ratio, indicating that \textit{Mfn2} deficiency potentially induces apoptosis through the Bcl-2 and Bax pathway.\textsuperscript{56} Depletion of \textit{Opa1} or mitofusins results in poor cell growth and enhances susceptibility to apoptotic stimuli because loss of the inner mitochondrial membrane protein \textit{Opa1} leads to drastic reorganization of mitochondrial cristae, fragmentation of mitochondria, efflux of cytochrome \textit{c}, and apoptosis.\textsuperscript{61} Moreover, excessive mitochondrial fission mediated by \textit{Drp1} and \textit{Fis1} produces dysfunctional mitochondrial fragments that show increased production of reactive oxygen species and are also more sensitive to mitochondrial permeability transition pore opening and \textit{Bax}/\textit{Bak} activation.\textsuperscript{49,63} In this study, we showed that patients with BD demonstrated increased levels of active caspase-3, which were shown to be negatively correlated with \textit{Mfn2} and \textit{Opa1}. Thus, the downregulation of \textit{Mfn2} and \textit{Opa1} and overexpression of \textit{Fis1} observed in BD patients can induce mitochondrial fission and apoptosis because mitochondrial fragmentation induced by \textit{Fis1} is followed by cytochrome \textit{c} release, caspase activation and cell death.\textsuperscript{64} Taken together, we suggest that an imbalance in mitochondrial fusion and fission towards fission causes mitochondrial fragmentation and may drive the cell into apoptosis, leading to the release of pro-apoptotic proteins, cristae remodeling, and

\begin{figure}
\centering
\includegraphics[width=\textwidth]{figure7.png}
\caption{Schematic diagram illustrating the disruption of the balance between mitochondrial fusion and fission in bipolar disorder (BD) patients, and also the modulation of Bcl-2 family. This imbalance in mitochondrial fusion and fission towards fission causes mitochondrial fragmentation and may directly drive the cell into apoptosis, leading to the release of pro-apoptotic proteins, cristae remodeling, and activation of caspase-3. Moreover, members of the Bcl-2 family may participate in the regulation of mitochondrial fission/fusion dynamics in BD patients.}
\end{figure}
activation of caspase-3. Moreover, Bcl-2 family members may participate in the regulation of mitochondrial fission/fusion dynamics in BD patients because Bcl-2 levels were markedly decreased in BD patients.\textsuperscript{12,15} and this protein has an antagonistic effect on mitochondrial fission machinery mediated by the mutually exclusive interactions of Bcl-2 and Drp1 with Fis1.\textsuperscript{65} In support of this hypothesis, we found that the levels of Bcl-xL and Bcl-xL/Bak dimer, members of the Bcl-2 family, were correlated with Mfn2 and Fis1 levels, suggesting that Bcl-2 family can regulate mitochondrial fission/fusion dynamics in BD patients (Figure 7).

Several studies have shown parallel alterations in central nervous system and peripheral cells of patients with BD. In addition, BD patients show higher rates of medical comorbidities, including cardiovascular disease, diabetes mellitus and obesity, which led some investigators to conceptualize BD as a multi-systemic disease.\textsuperscript{66} In other words, peripherally-measured parameters can not only provides biomarkers of illness, but are also thought to influence behavior, cognitive and functional parameters. To corroborate this hypothesis, our results showed that individuals with worse functional status (as shown by lower GAF and higher FAST scores) showed significantly lower levels of fusions proteins Mfn2 and Opa1 and higher levels of Fis1. In the same line, we also found a negative correlation between functional status and Bcl-xL and Bcl-xL/Bak dimer. Accordingly, the changes in fission/fusion protein levels and anti-apoptotic factors observed in PBMCs from BD patients can support the relevance of the peripheral findings to mitochondrial abnormalities reported in the central nervous system of BD patients.

Our results should be interpreted in light of their limitations. First, our sample size was relatively small and this may limit the interpretation of our results. Second, it cannot be excluded that long-term treatment with psychiatric medications may affect the mitochondrial network. Third, our study was limited to mitochondrial analyses that could be performed on frozen PBMC samples, which precluded us from assessing of other relevant mitochondrial analyzes that could be performed on frozen PBMC samples, thus precluding us from assessing of other relevant mitochon- drial parameters, such as oxygen consumption. Thus, future studies are necessary to verify these findings in larger and fresh samples, allowing the specific preparation of tissues for the analysis of mitochondrial morphology. These studies will be able to evaluate the morphological consequences of the imbalance of mitochondrial dynamics in patients with BD.

In conclusion, our results demonstrate significant changes in the expression of mitochondrial fission and fusion proteins and survival-related proteins in PBMCs from BD. Our findings in PBMCs of patients with BD support a link between mitochondrial dysfunction and the pathophysiology of BD, and the fact that these changes are seen in peripheral PBMCs suggests that the pathophysiological processes active in the disorder are body-wide and implicate circulating factors.\textsuperscript{69} Finally, understanding the mitochondrial network dynamics in BD and its interconnection with cellular signaling pathways may contribute to a more comprehensive understanding of the biological processes in this disease and may ultimately lead to the development of new treatment strategies.\textsuperscript{70}

\section*{CONFLICT OF INTEREST}

The authors declare no conflict of interest.

\section*{ACKNOWLEDGMENTS}

This study was supported in part by grants from the Pat Rutherford, Jr Endowed Chair in Psychiatry (JCS), John S. Dunn Foundation from United States (JCS) and NIH (R01MH085665-01A1; JCS). MB is supported by a NHMRC Senior Principal Research Fellowship 1059660. The Center of Excellence on Mood Disorders and Translational Psychiatry Program (USA) is funded by the Department of Psychiatry and Behavioral Sciences, McGovern Medical School, The University of Texas Medical School at Houston. The Laboratory of Neurosciences (Brazil) is one of the centers of the National Institute for Molecular Medicine (INCT-MM) and one of the members of the Center of Excellence in Applied Neurosciences of Santa Catarina (NENASC). Giselli Scaini thanks the Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) for a postdoctoral fellowship (205680/2014-3).

\section*{REFERENCES}

1. Menkangas RR, Rr Rn, He JP, Kessler RC, Lee S, Sampson NA et al. Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry 2011; 68: 241–251.

2. Osby U, Brandt L, Corella N, Ekbom A, Sparen P. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry 2001; 58: 844–850.

3. Martinez-Aran A, Vieta E, Torrent C, Sanchez-Moreno J, Goikolea JM, Salamero M et al. Functional outcome in bipolar disorder: the role of clinical and cognitive factors. Bipol Disord 2007; 9: 103–113.

4. Berk M, Kozhizinski F, Andreazza AC, Dean OM, Giorlando F, Maes M et al. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev 2011; 35: 804–817.

5. Torres IJ, Boudreau VG, Yatham LN. Neuropsychological functioning in euthymic bipolar disorder: a meta-analysis. Acta Psychiatr Scand Suppl 2007; 434: 17–26.

6. Rosa AR, Gonzalez-Oteigo I, Gonzalez-Pinto A, Echeburua E, Comes M, Martinez-Arango A et al. One-year psychosocial functioning in patients in the early vs. late stage of bipolar disorder. Acta Psychiatr Scand 2012; 125: 335–341.

7. Elshahawi HH, Essawi H, Rabie MA, Mansour SA, Moushe M, Mansour AN. Cognitive functions among euthymic bipolar I patients after a single manic episode versus recurrent episodes. J Affect Disord 2011; 130: 180–191.

8. Cannon M, Jones P, Gillyary C, Rifkin L, McKenzie K, Foerster A et al. Premorbid social functioning in schizophrenia and bipolar disorder: similarities and differences. Am J Psychiatry 1997; 154: 1544–1550.

9. Rosa AR, Magalhaes PV, Czepielewski L, Sulzbach MV, Gai PD, Vieta E et al. Clinical staging in bipolar disorder: focus on cognition and functioning. J Clin Psychiatry 2014; 75: e450–e456.

10. Scola G, Kim HK, Young LT, Andreazza AC. A fresh look at complex I in microarray data: clues to understanding disease-specific mitochondrial alterations in bipolar disorder. Biol Psychiatry 2013; 73: 64–65.

11. Gould TD, Manji HK. Signaling networks in the pathophysiology and treatment of mood disorders. J Psychiatr Res 2002; 53: 687–697.

12. Kim HW, Rapoport SI, Rao JS. Altered expression of apoptotic factors and synaptic markers in postmortem brain from bipolar disorder patients. Neurol Bio Dis 2010; 37: 596–603.

13. Gigante AD, Young LT, Yatham LN, Andreazza AC, Nery FG, Grinberg LT et al. Morphometric post-mortem studies in bipolar disorder: possible association with oxidative stress and apoposis. Int J Neuropsychopharmacol 2011; 14: 1075–1089.

14. Green DR, Reed JC. Mitochondria and apoptosis. Science 1998; 281: 1309–1312.

15. Moutsatsou P, Trioporis JN, Salpeas V, Bei E, Alevizos B, Anagnostara C et al. Peripheral blood lymphocytes from patients with bipolar disorder demonstrate apoptosis and differential regulation of advanced glycation end products and S100B. Clin Chem Lab Medicine 2014; 52: 999–1007.

16. Bei E, Salpeas V, Pappa D, Anagnostara C, Alevizos V, Moutsatsou P. Phosphor- ylation status of glucocorticoid receptor, heat shock protein 70, cytochrome c and Bax in lymphocytes of euthymic, depressed and manic bipolar patients. Psychoneu- roendocrinology 2009; 34: 1162–1175.

17. Fries GR, Vasconcelos-Moreno MP, Gubert C, Santos BT, da Rosa AL, Eisele B et al. Early apoptosis in peripheral blood mononuclear cells from patients with bipolar disorder. J Affect Disord 2014; 152-154: 474–477.

18. Nitzuma K, Yoshioka H, Chen H, Kim Gs, Jung JE, Katsu M et al. Mitochondrial and apoptotic neuronal death signaling pathways in cerebral ischemia. Biochim Bio- phys Acts 2010; 1802: 92–99.

19. Pieczynik SR, Neustadt J. Mitochondrial dysfunction and molecular pathways of disease. Exp Mol Pathol 2007; 83: 84–92.

20. Kroemer G, Reed JC. Mitochondrial control of cell death. Nat Med 2000; 6: 513–519.

21. Arnout D, Grodet A, Lee YJ, Estajuer J, Blackstone C. Release of OPA1 during apoptosis participates in the rapid and complete release of cytochrome c and subsequent mitochondrial fragmentation. J Biol Chem 2005; 280: 35742–35750.

22. Arnout D, Rismanci N, Grodet A, Roberts RG, Seeburg DP, Estajuer J et al. Bax/ Bak-dependent release of DDP/TIMM8a promotes Drp1-mediated mitochondrial fission and mitoptosis during programmed cell death. Curr Biol 2005; 15: 2112–2118.

23. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E et al. The Mini-International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998; 59(Suppl 20): 22–33, quiz 34-57.
Bipolar disorder and mitochondrial function
G Scaini et al

24 Williams, JB, Kobak KA. Development and reliability of a structured interview guide for the Montgomery Asberg Depression Rating Scale (SIGH-A). Br J Psychiatry 2008; 192: 52–58.

25 Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978; 133: 429–435.

26 American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 3rd edn (DSM-III). Arlington, VA, American Psychiatric Press, 1980.

27 Tsuang MT, Opler LA, D’Souza-Burke R, Wender PH. The prevalence of schizoaffective disorder compared with schizophrenia and mood disorders. Br J Psychiatry 1991; 159: 171–177.

28 Iverson CM, Keshavan MS. Neuroanatomical abnormalities in bipolar disorder: a neurobiological approach. J Affect Disord 2010; 127: 9–22.

29 de la Fuente NR, Mendlewicz J, Chu P, Geller B, Meltzer HY. Evidence for the existence of mood disorders in bipolar II disorder. J Affect Disord 2014; 165: 1–7.

30 Birmaher B, Ryan N, Williamson D, Dahl RM, Brent D. Bipolar disorder in children and adolescents. J Clin Psychiatry 2001; 62: 559–570.

31 Fochtmann NL, Dunn SL, O’Connor SJ, Types of bipolar disorder. J Clin Psychiatry 2012; 73 (Suppl. 16): 27–35.

32 Baker T, Coghill J, Mayson M, French N, Cooper S, Mitchell P. Symptom-free inter-episode functioning in bipolar disorder: a community-based study. J Affect Disord 2014; 165: 35–41.

33 Singh P, Wilson DA, Fordyce K, Linn J, Ketter TA. Longitudinal changes in the mood symptoms of bipolar I disorder and the differential response to antidepressant treatment. Bipolar Disord 2014; 16: 469–478.

34 Addington J, Zhang L, Ketter TA, Nurnberger JI, Mischoulon D. Longitudinal clinical and neurocognitive changes over 17 years in bipolar I disorder. Am J Psychiatry 2010; 167: 661–668.

35 Addington J, Zhang L, Ketter TA, Nurnberger JI, Mischoulon D. Longitudinal changes in cognitive function over 17 years in bipolar I disorder. Am J Psychiatry 2010; 167: 661–668.

36 Addington J, Zhang L, Ketter TA, Nurnberger JI, Mischoulon D. Longitudinal changes in cognitive function over 17 years in bipolar I disorder. Am J Psychiatry 2010; 167: 661–668.

37 Addington J, Zhang L, Ketter TA, Nurnberger JI, Mischoulon D. Longitudinal changes in cognitive function over 17 years in bipolar I disorder. Am J Psychiatry 2010; 167: 661–668.

38 Addington J, Zhang L, Ketter TA, Nurnberger JI, Mischoulon D. Longitudinal changes in cognitive function over 17 years in bipolar I disorder. Am J Psychiatry 2010; 167: 661–668.

39 Addington J, Zhang L, Ketter TA, Nurnberger JI, Mischoulon D. Longitudinal changes in cognitive function over 17 years in bipolar I disorder. Am J Psychiatry 2010; 167: 661–668.

40 Addington J, Zhang L, Ketter TA, Nurnberger JI, Mischoulon D. Longitudinal changes in cognitive function over 17 years in bipolar I disorder. Am J Psychiatry 2010; 167: 661–668.

41 Addington J, Zhang L, Ketter TA, Nurnberger JI, Mischoulon D. Longitudinal changes in cognitive function over 17 years in bipolar I disorder. Am J Psychiatry 2010; 167: 661–668.

42 Addington J, Zhang L, Ketter TA, Nurnberger JI, Mischoulon D. Longitudinal changes in cognitive function over 17 years in bipolar I disorder. Am J Psychiatry 2010; 167: 661–668.

43 Addington J, Zhang L, Ketter TA, Nurnberger JI, Mischoulon D. Longitudinal changes in cognitive function over 17 years in bipolar I disorder. Am J Psychiatry 2010; 167: 661–668.

44 Addington J, Zhang L, Ketter TA, Nurnberger JI, Mischoulon D. Longitudinal changes in cognitive function over 17 years in bipolar I disorder. Am J Psychiatry 2010; 167: 661–668.

45 Addington J, Zhang L, Ketter TA, Nurnberger JI, Mischoulon D. Longitudinal changes in cognitive function over 17 years in bipolar I disorder. Am J Psychiatry 2010; 167: 661–668.
Author/s:
Scaini, G; Fries, GR; Valvassori, SS; Zeni, CP; Zunta-Soares, G; Berk, M; Soares, JC; Quevedo, J

Title:
Perturbations in the apoptotic pathway and mitochondrial network dynamics in peripheral blood mononuclear cells from bipolar disorder patients

Date:
2017-05-02

Citation:
Scaini, G., Fries, G. R., Valvassori, S. S., Zeni, C. P., Zunta-Soares, G., Berk, M., Soares, J. C. & Quevedo, J. (2017). Perturbations in the apoptotic pathway and mitochondrial network dynamics in peripheral blood mononuclear cells from bipolar disorder patients. TRANSLATIONAL PSYCHIATRY, 7 (5), https://doi.org/10.1038/tp.2017.83.

Persistent Link:
http://hdl.handle.net/11343/259225

File Description:
Published version

License:
CC BY